Catalyst Pharmaceutical Partners said yesterday that it has exclusively licensed from Northwestern University the commercial rights to GABA aminotransferase inhibitors and derivatives of the anti-epileptic drug vigabatrin.

Read the original article
Brought to you by Yahoo! News

Return to Epilepsy News